<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>FLT3-ITD mutation &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/flt3-itd-mutation/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 10:12:11 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>FLT3-ITD mutation &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Decoding the Role of a Crucial Protein in Aggressive Blood Cancer Growth, Opening Doors to Targeted Treatments</title>
		<link>https://bioengineer.org/decoding-the-role-of-a-crucial-protein-in-aggressive-blood-cancer-growth-opening-doors-to-targeted-treatments/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 25 Jun 2025 11:49:45 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Acute myeloid leukemia (AML)]]></category>
		<category><![CDATA[epigenetic therapy]]></category>
		<category><![CDATA[FLT3-ITD mutation]]></category>
		<category><![CDATA[MYC oncogene regulation]]></category>
		<category><![CDATA[SETD1B protein]]></category>
		<guid isPermaLink="false">https://bioengineer.org/decoding-the-role-of-a-crucial-protein-in-aggressive-blood-cancer-growth-opening-doors-to-targeted-treatments/</guid>

					<description><![CDATA[Acute myeloid leukemia (AML) remains one of the most formidable hematological malignancies, characterized by the rapid proliferation of malignant myeloid cells within the bone marrow and peripheral blood. Despite advances in chemotherapy and targeted therapeutics, many subtypes of AML resist treatment, leading to frequent relapses and poor patient outcomes. A groundbreaking study conducted by researchers [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">250371</post-id>	</item>
	</channel>
</rss>
